MIVetsCan: Cannabidiol (CBD)-Care Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pain, Chronic
Interventions
DRUG

Placebo

Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

DRUG

Cannabidiol

Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Michigan, State of, Licensing and Regulatory Affairs

UNKNOWN

lead

Kevin Boehnke

OTHER